Palazzo LL, et al. - Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, researchers evaluated the variations and trends in genetic testing and treatment with erlotinib among metastatic non-small cell lung cancer (NSCLC) cases in this retrospective analysis. They noted an association of erlotinib treatment with race (OR=0.58, black vs white; OR=2.45, Asian vs white) for untested subjects. The prevalence of such relationship was more among female patients. They also found that erlotinib treatment was less likely among low-income patients (for tested patients). Stability was noticed in the racial disparity over time whereas the income-based disparity grew wider.